SS-31 Guide & Protocols

SS-31, also called elamipretide, has more human trial history behind it than almost anything else on this site, including one narrow FDA approval. It also has an unusually large gap between the amount that was actually tested and the amount most people run. Below is the amount most commonly discussed, how it's cycled and stacked, and how it compares to MOTS-c if you're weighing the two mitochondrial-support peptides against each other.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target dose you're working with.

What it is

SS-31 is a small synthetic peptide that concentrates in the inner mitochondrial membrane and is proposed to stabilize cardiolipin, a molecule essential to how mitochondria generate energy. It's sold as a research chemical under the name SS-31, though its clinical name is elamipretide, and under the brand name Forzinity it received FDA accelerated approval in September 2025 for improving muscle strength in Barth syndrome, a rare genetic mitochondrial condition. Outside that one narrow use, it remains investigational and unapproved.

What people use it for

SS-31 shows up most in mitochondrial-support and cellular-energy conversations, often alongside general interest in cardiac and skeletal muscle aging. It gets discussed in the same circles as MOTS-c, since both are framed as mitochondrial research, though they work through different proposed mechanisms. Its unusually deep human trial record, covering heart failure, mitochondrial myopathy, and heart attack recovery, is part of what draws attention to it, even though most of those trials didn't produce a positive result outside Barth syndrome.

Formulations

SS-31 ships as a lyophilized (freeze-dried) powder that needs reconstitution before use. Vendors most commonly sell 5 mg and 10 mg vials. Clinical trials used both subcutaneous injection and intravenous infusion; the research-market product is sold for subcutaneous use only, since IV administration isn't something a research vendor's product is set up for.

Dosing protocols

There's a real gap here worth naming directly: the trials behind SS-31's one FDA approval, and behind every other trial in its record, dosed elamipretide at 40 mg daily. What circulates in research and wellness circles is far below that.

See the SS-31 research notes for the trial record and mechanism before reading the dosing itself.

Most commonly referenced pattern

5 to 10 mg daily, subcutaneous injection. This is the range referenced most often across research and wellness dosing guides, generally without a named source behind the specific figure.

A lower, introductory variant

2 to 5 mg daily, subcutaneous injection. Framed as a starting point before moving toward the range above, with the same lack of traceable origin.

A higher variant, less commonly discussed

10 to 20 mg daily. Shows up less often and closer to the low end of what a physician-supervised protocol might reference, still well under the 40 mg trial dose.

Dr. Alex Tatum, a urologist who reviews research compounds on his channel, published a walkthrough of SS-31's trial record in July 2026 and made a point worth carrying into any reading of the numbers above: reports of running SS-31 at a low single-digit-to-low-double-digit dose and feeling nothing aren't much of a test of the compound, since the full 40 mg trial dose also failed to show the improvement it was designed to detect in several trials. Neither observation settles anything about what the community dose actually does, and that's honestly where the evidence leaves it.

Cycling guidelines

Continuous daily dosing for 4 to 8 weeks, followed by a break of similar length, is the pattern most commonly described, closer to a maintenance-style schedule than the short defined courses seen with some other peptides on this site. We couldn't find a source for where that specific window came from.

Signs a course is commonly stopped early:

• Persistent injection-site reaction beyond mild, brief redness
• Any new symptom you can't otherwise explain
• No noticed change after a full cycle, which some people treat as a reason to reassess rather than continue automatically

Stacking

Most commonly paired stack: SS-31 and MOTS-c.

Rationale: both work on mitochondrial function through different angles, structural protection of the inner membrane for SS-31, cellular energy signaling for MOTS-c, which is why the two get discussed together constantly in longevity-adjacent conversations.

Protocol as run: each peptide on its own schedule from above, run over the same general weeks rather than on one matched timetable.

Why it's paired: the mitochondrial framing is the whole draw for both compounds, so people researching one tend to look at the other, not because a combination has been studied together.

Lighter stacks: some longevity-focused stacks add SS-31 alongside NAD+-adjacent compounds, on the reasoning that cellular energy and mitochondrial signaling overlap. This is rationale plus a loosely matched schedule, not a protocol with dedicated combination data.

Combinations to approach carefully: no specific drug interaction has been characterized for SS-31, but anyone on medication for a cardiac condition should treat stacking it with anything else with real caution, given how much of SS-31's own trial record centers on cardiac outcomes.

Expected results timeline

Early days: mostly an adjustment period for the injection routine itself. Anything noticed in the first several days is more likely the routine or placebo than the compound doing its work.

During a cycle: this is where most self-reported changes cluster, energy and general stamina, entirely self-reported and not measured against a control group.

Cumulative, across repeated cycles: any real cardiac or muscular-aging marker change would only show up here, and it's the piece with the least evidence behind it at community doses, since the trial data that exists used a dose several times higher.

What to expect realistically: a compound with an unusually deep human trial record and a real approval, and, at the same time, a community dose far below what any of those trials tested. Energy changes during a cycle are the most commonly described signal. A measurable cardiac or mitochondrial marker change without clinical testing isn't a reasonable expectation.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target dose.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe.
4. A subcutaneous site is chosen, commonly the abdomen or outer thigh, with sites rotated daily.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. Each injection is commonly logged by date, amount, and site, so a multi-week cycle doesn't rely on memory partway through.

Side effects and safety

Common: mild redness or irritation at the injection site, the most frequently reported issue across the trial record as well as anecdotal use.

Less common: mild headache or fatigue reported anecdotally at community doses, not measured in any controlled way.

What we do know: unusually for a research peptide, SS-31 has an actual human safety record behind it, hundreds of people dosed in monitored trials, mostly at 40 mg daily, well above the community range. That record is a genuine point in its favor, though it says less than it might seem to about tolerability at the lower, untested doses most people actually run.

Contraindications: anyone with a diagnosed cardiac condition should approach this compound with real caution and ideally involve a physician, given how central cardiac outcomes are to SS-31's own trial record. Pregnancy, breastfeeding, and use in minors all have no data behind them outside the approved Barth syndrome population and should be avoided.

Drug interactions: none have been formally characterized for research use. That's an absence of data, not evidence of safety, and it's a reasonable point of caution for anyone on cardiac medication specifically.

SS-31 vs. MOTS-c

If you're weighing SS-31 against something else, MOTS-c is the compound people actually cross-shop it against, since both get framed as mitochondrial-support research and often show up in the same conversations.

Choose SS-31 if: mitochondrial structural protection is the more specific interest, and you want a compound with considerably more human trial history behind its mechanism, even if not behind the amount typically self-administered.

Choose MOTS-c if: the exercise-mimetic and metabolic angle is what you're after.

Stacking the two: commonly discussed together given the shared mitochondrial framing, run on separate schedules rather than one matched protocol. See the MOTS-c research notes for pricing and vendor info.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C; stable at -20°C for long-term storage. Avoid repeated freeze-thaw cycles.

Reconstituted solution: refrigerate, and plan to use it within about 28 days once water has been added, following whatever window your vendor specifies. That 28-day figure comes from the same compounding-pharmacy standard used industry-wide for a bacteriostatic-water solution; SS-31's deep trial record concerns the dosing amount, not reconstituted-solution stability, so there's no compound-specific reason to expect a different window.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or reconstituted liquid
• A cycle that produces none of the previously noticed subjective effects, though this is a soft signal at best

FAQ

Why does the community dose look so much lower than what's in the news about the FDA approval? Because it is. The Barth syndrome approval and every other trial in SS-31's record used 40 mg daily. Most community protocols run 5 to 10 mg, sometimes less.

Does that mean the lower dose doesn't work? Nobody knows. It hasn't been tested at that amount, and the full 40 mg dose also failed to show the improvement it was designed to detect in several trials outside Barth syndrome.

Is SS-31 the same thing as Forzinity? Forzinity is the FDA-approved brand name for elamipretide, the same molecule sold as a research chemical under the name SS-31. The approval covers Barth syndrome specifically, not general use.

How long is a typical cycle? Most commonly 4 to 8 weeks of continuous daily dosing, followed by a break of similar length, though the specific window has no traceable source.

Is it safe to combine with MOTS-c? No dedicated combination study exists. The two are commonly discussed together given the shared mitochondrial framing, run on separate schedules.

Is there real human safety data? Yes, more than most peptides on this site, hundreds of people dosed in monitored trials, though mostly at a dose well above what's typically self-administered.

How is it stored? Refrigerated as a powder, refrigerated and used within about 28 days once reconstituted.

What's the difference between a 5 mg and 10 mg vial? Only the concentration and how many vials your cycle requires; the reconstitution calculator handles the arithmetic either way.

Bottom line

Key dosing takeaways:

• 5 to 10 mg daily, subcutaneous, is the amount most commonly referenced, well below the 40 mg dose used in every trial behind SS-31's approval
• SS-31 has more human trial history than almost anything else on this site, but the trial dose and the community dose are not the same thing
• Anyone with a cardiac condition should treat this one with particular caution and involve a physician, given how central cardiac outcomes are to its trial record

Best practices:

• Comparing vendors by cycle total in milligrams, not by vial count, is where the real price differences show up
• Logging each injection keeps a multi-week cycle from relying on memory
• Reading the trial record on the research notes page before treating any community dose as validated by that record is worth the few minutes it takes

Works best for people who:

• Are drawn to the mitochondrial structural-protection angle specifically
• Want a compound with real human trial history to read, even knowing the community dose sits well below what was tested
• Are comfortable researching it alongside MOTS-c as part of a broader mitochondrial-focused interest